A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CAMILLA

Most Recent Events

14 Jan 2025 Planned End Date changed from 30 Nov 2027 to 31 Jan 2028.
14 Jan 2025 Planned primary completion date changed from 30 Nov 2026 to 31 Jan 2027.
14 Jan 2025 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight